Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26825316)
Watch
English
Universes collide: combining immunotherapy with targeted therapy for cancer
scientific article
In more languages
edit
Statements
instance of
scholarly article
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
review article
1 reference
stated in
Europe PubMed Central
title
Universes collide: combining immunotherapy with targeted therapy for cancer
(English)
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
main subject
immunotherapy
1 reference
based on heuristic
inferred from title
author
Zachary A. Cooper
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
Jennifer Wargo
series ordinal
1
object named as
Jennifer A Wargo
1 reference
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
author name string
Keith T Flaherty
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
language of work or name
English
1 reference
stated in
PubMed
publication date
13 November 2014
1 reference
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
published in
Cancer Discovery
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
volume
4
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
issue
12
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
page(s)
1377-1386
1 reference
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
cites work
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
BRAF mutations in hairy-cell leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
MEK1 mutations confer resistance to MEK and B-RAF inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Mutations of the BRAF gene in human cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Hepatotoxicity with combination of vemurafenib and ipilimumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Restoring function in exhausted CD8 T cells during chronic viral infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Immunologic correlates of the abscopal effect in a patient with melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
7 April 2017
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Targeted therapies to improve tumor immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
BRAF mutation in thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
CTLA-4: new insights into its biological function and use in tumor immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 September 2017
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
31 May 2018
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
31 May 2018
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
31 May 2018
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
31 May 2018
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 November 2018
Breakthrough of the year 2013. Cancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 November 2018
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 November 2018
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 November 2018
Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 November 2018
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 November 2018
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258160
retrieved
28 November 2018
Identifiers
DOI
10.1158/2159-8290.CD-14-0477
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2831254
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
OpenCitations bibliographic resource ID
2831254
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2831254
PMC publication ID
4258160
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2831254
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
PubMed publication ID
25395294
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
2831254
stated in
Europe PubMed Central
PMC publication ID
4258160
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395294%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit